We believe that we are in the early stages of a major innovation cycle in biopharmaceuticals.

Important scientific discoveries are translating into major clinical breakthroughs, enabled by the advent of novel therapeutic modalities such as genetic medicines and cellular therapies. Unlike in prior decades, where R&D was concentrated within large pharmaceutical companies, today much of the innovation is occurring within smaller biopharmaceutical companies. At Commodore, we strive to be good partners to these companies as they work to bring safe and effective new medicines to patients around the world.